Investments, Funding & Disinvestment

The initiative builds on PureLab’s expansive diagnostic footprint, which includes more than 145 laboratories, over 1,400 licensed clinical professionals, and more than 50 accreditations across its testing network.

The new 250,000-square-foot (23,226-square-metre) Bellwether Laboratory will significantly expand global production capacity for actinium-225 (Ac-225).

The financing consortium includes Proparco, the European Investment Bank through the Human Development Accelerator initiative, and the International Finance Corporation.

Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.

The expansion will also include upgrades to clinical infrastructure and medical equipment, enabling the hospital to deliver more integrated and specialised healthcare services while responding to rising patient demand.

The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.

The new facility is designed to address the growing prevalence of sleep disorders, which remain among the most underdiagnosed health conditions despite their serious impact on long-term wellbeing.

The new capability strengthens Abu Dhabi’s broader preventive healthcare strategy by equipping public and private sector institutions with faster access to highly accurate toxicology data.

The new office will host Insulet’s full regional leadership and operational teams, serving as the company’s central hub for clinical collaboration, partner development, market access initiatives, and talent investment across the region.

This year’s event also builds on commitments outlined in the Durban Promise, adopted during CPHIA 2025, which calls for stronger governance, increased investment in primary healthcare systems, and greater regional collaboration to achieve health sovereignty.